Liver transplantation for patients with hepatitis C virus (HCV) and human immunodefi ciency virus (HIV) remains challenging. The advent of highly active antiretroviral therapy (HAART) for HIV has reduced mortality from opportunistic infection related to acquired immunodeficiency syndrome dramatically, while about 50% of patients die of end-stage liver cirrhosis resulting from HCV. In Japan, liver cirrhosis frequently develops after HCV-HIV coinfection resulting from previously transfused infected blood products for hemophilia. The problems of liver transplantation for those patients arise from the need to control calcineurin inhibitor with HAART drugs, the diffi culty of using interferon after liver transplantation with HAART, and the need to control intraoperative coagulopathy associated with hemophilia. We review published reports of liver transplantation for these patients in the updated world literature.
Introduction
According to a report compiled by the Japanese Ministry of Health, Labour and Welfare in October 2006, the number of HIV-infected patients in Japan was 8 071 (6 275 males and 1 796 females), and this number has increased further since. 1 In 2008 there were 1 557 new cases reported, including 1 126 HIV-positive cases and 431 acquired immunodefi ciency syndrome (AIDS) cases. 2 The possible routes of infection include sexual contact, through contaminated or unheated blood products, and mother-to-child transmission. When HIV infection is contracted through blood products, there is often coinfection with HCV.
Since 1995, there has been a major change in the cause of death of HIV-infected patients. It is believed that the major factor contributing to these trends is the improved HIV control achieved in recent years with highly active antiretroviral therapy (HAART). 3 HAART is defi ned as a combination of drugs from different classes of HIV therapy, comprising nucleoside reverse transcriptase inhibitors (NRTIs), and either nonnucleoside reverse transcriptase inhibitors (NNRTIs) or a protease inhibitor (PI) . If the compliance is 95% or more, this therapy is successful in more than 50% of patients. [3] [4] [5] This review focuses on liver transplantation in Japanese patients with HIV and HCV, especially those in whom the disease was caused by receiving contaminated blood products in the past and who may be candidates for liver transplantation.
Epidemiology of HIV-HCV Coinfection in Patients with Hemophilia in Japan
According to a survey by the Ministry of Health, Labour and Welfare in the 2008 fi scal year in Japan, 602 patients with hemophilia A (factor 8 defi ciency) and 183 with hemophilia B (factor 9 defi ciency) were alive with HIV infection (Table 1) . 6 Among these, 524 with hemophilia A (87%) and 162 with hemophilia B (89%) also had HCV infections and liver disease (Table 2) . Of the 524 persons with hemophilia A, 33 (6.3%) had cirrhosis, 5 (0.9%) had liver cancer, and 2 (0.4%) had liver failure. Two of these patients underwent a liver transplant procedure. It is highly possible that about 50 of the patients with cirrhosis may be candidates for liver transplantation in the future. In fact, this survey revealed that onethird of the deaths of HIV-HCV coinfected patients with blood-borne diseases were caused by liver disease.
A characteristic that should be taken into account when using imported blood products is that the proportion of patients with HCV genotype 1b is low, at 25% vs 70% in general for Japanese, and the proportion of patients with HCV genotype 3a is high, at 23%. Also, one study found that the proportion of patients with HIV-HCV coinfection with an HCV titer below the level of sensitivity of the assay was signifi cantly lower than the proportion of such patients among non-HIV cases of HCV infection, at 44.0% vs 55.4%, respectively. 7 There have been a few reports from other countries on the problems associated with HCV and HIV infections in hemophiliac patients. 8, 9 Liver Transplantations in HIV-HCV Coinfected Patients
Indications for Liver Transplantation in Patients with HIV-HCV Coinfection
Regardless of the presence of hemophilia, the indications for and methods of liver transplantation are the same for patients with HIV-HCV coinfection. Therefore, information on liver transplantation for HIV-HCV coinfected patients without hemophilia is presented in this section. In fact, after successful liver transplantation, hemophilia can normally be cured. In principle, as for a non-HIV-infected patient, liver transplantation is indicated for patients with type C cirrhosis in liver failure and no expectation of a long-term prognosis. [10] [11] [12] [13] [14] Liver transplantation is also indicated for patients not yet in liver failure, but with severe liver damage caused by HAART, especially those with chronic hepatitis C, who need to suspend or stop HAART. [15] [16] [17] [18] For patients receiving HAART, the indication needs to be considered in terms of both hepatic reserve and status of the HIV infection. Liver transplantation may also be indicated for hepatocellular carcinoma that develops during follow-up. 19 The conditions for liver transplantation are often defi ned as follows: AIDS symptoms have not surfaced; the CD4+ lymphocyte count is 200-250/μl or above; and as a result of HAART, the amount of HIV in the blood is below the level of sensitivity of the assay. However, there are cases of pancytopenia resulting from portal hypertension and, as such, some institutions believe that the criterion for liver transplantation resolved be a CD4+ lymphocyte count of 100/μl or more. [19] [20] [21] [22] Therefore, an issue to be resolved is whether 
Results of Liver Transplantation for Patients with HIV-HCV Coinfection
Liver transplantation from deceased donors has been performed in HIV patients since the 1980s in the United States and Europe. Initially the results were poor, with survival rates of only about 47%, 24 but this has improved remarkably since the introduction of HAART (Table  3 ). According to a review article published in 2004, 51 HIV-positive patients received liver transplantation between 1996 and 2004 worldwide, with liver damage caused by HCV being the indication in 68%. Since 1997, liver transplantation has been performed in 29 HIV patients at the University of Pittsburgh: 26% of these patients were hemophiliac and 89% were HCV-positive. 25 According to a retrospective study by the United Network for Organ Sharing, involving 138 HIV-positive persons and 30 520 HIV-negative persons and evaluating liver transplantation, from 1997 when HAART was introduced and thereafter, the prognosis of patients who were only HIV-positive was relatively good. 26 In this study, the prognosis of HIV-HCV coinfected patients was worse than that of patients who were positive only for HIV. A series of reports are listed in Table 3 . 13, 20, 21, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] In reality, in addition to those listed there have been many sporadic reports, such as reviews, regarding expectations for liver transplantation, and assessments of indications.
A recent important study in France, on 14 patients, provided details on interferons, HAART therapy, and liver fi brosis. 33 In all patients, the preoperative amount of HIV in the blood was below the level of sensitivity, and the CD4+ T-cell counts ranged from 85 to 1 015. As for calcineurin inhibitors, tacrolimus 0.5 mg per week was started in the 2nd week after surgery in principle; however, there were fi ve cases (36%) of an overdose. HAART was recommenced in the 2nd week after surgery, resulting in the long-term administration of steroids. Liver biopsies in the 12th month after liver transplantation revealed one case of fi brosing cholestatic hepatitis (FCH), one case of fi brosis stage F3, two cases of F2, and fi ve cases of F1. The prognosis after transplantation was thought to be encouraging, since there was only one death as a result of FCH in the series.
Living Donor Liver Transplantation for Patients with HIV-HCV Coinfection
The Koike Group of the Ministry of Health, Labour, and Welfare reported seven cases of living donor liver transplantation (LDLT) for HIV-HCV coinfected patients with hemophilia at The University of Tokyo, and one at Hiroshima University. 35, 36 The HCV genotypes were 1a and 1b (n = 1), 1b and 3a (n = 1), 2a (n = 1), 2a and 2b (n = 1), and 3a and 1b (n = 1). The HVC-RNA levels ranged from 2.8 to 1 410 kIU/ml, the HIV-RNA levels in two cases were 50 copies/ml or less, being below the sensitivity level, and the CD4+ T-cell counts ranged from 120 to 618/μl and were 250/μl or less in two cases. At the time of the report in 2005, four patients were alive. Small bowel bleeding (suspected cytomegalovirus enteritis) and graft dysfunction were cited as the causes of death of the nonsurviving patients. Interestingly, interferon therapy was given after surgery to the surviving patients, whereas it was suspended in the two patients who died. HAART therapy was not given to one patient on the grounds that the HIV virus disappeared as the interferon treatment progressed. The report stated that the administration of factor 8 products was never required after surgery for patient #1.
Living donor liver transplantation from a hemophilia carrier was reported in 2002, 37 and it seems that LDLT has been performed in up to 10 patients in Japan. As noted in the section on epidemiology, there are some 50 patients coinfected with HIV-HCV from blood products, in whom liver failure has developed. They, like other patients with chronic hepatitis, may be candidates for liver transplantation, so it is necessary to collect suffi cient information.
Problems with Liver Transplantation in HIV-HCV Coinfected Patients with Hemophilia The Blood Concentration of the Calcineurin Inhibitor Used in Combination with HAART Is Increased
The risk of opportunistic infections caused by a delay in starting HAART and the appropriate time to start HAART has not been established. Moreover, early initiation of the therapy is associated with a high risk of drug-induced liver damage. 38, 39 A new drug, Ralteglavir, does not interfere with the metabolism of the calcineurin inhibitor, and might reduce the chance of overshooting the trough level of the calcineurin inhibitor. 40 
Progression of HCV Recurrence Is Accelerated in These Patients Compared with Those Who Are Only HIV-Positive
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The HIV virus population dynamics manifest via the immune systems, which are targeted by antiviral drugs such as interferon and ribavirin as well as the HAART drugs. [42] [43] [44] [45] The best time to start interferon treatment and other post-transplantation measures to prevent HCV, optimal immunosuppressive regimens, and ways of monitoring drug blood levels are being studied, and further reports are expected. [46] [47] [48] [49] [50] [51] According to a review on the effects of interferon treatment after liver transplantation, the SVR rate ranges from 0% to 50%. This article reported that there had been many side effects in HIV-positive patients, especially caused by anemia and a low white blood cell count, and that the continuation of treatment for such patients had been made possible by administration of the growth factor. 52 
Some Studies Refer to the Correlation Between T-Cell Counts and Acute Rejection
In practice, some studies showed the rate of acute cellular rejection to be similar, regardless of HIV positivity. 11, 53 Induction therapy without steroids has also been attempted, 54 and the rate of opportunistic infection is reported to be similar after organ transplantation in HIV-positive patients. 20 Thus, the number of CD4+ lymphocytes present prior to liver transplantation is an important factor.
HAART Drugs Can Cause Hepatic Toxicity
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If HAART drugs induce liver failure, the best HAART drug to use after liver transplantation must be selected carefully. HAART drug toxicity can also induce complications with acute cellular rejection or other hepatic problems after liver transplantation. A liver biopsy may be needed to elucidate the real cause. Noncirrhotic portal hypertension has recently been reported in HIVpositive patients. HAART drugs may be related to those unresolved pathogeneses. 56 
The Control of Infection After Liver Transplantation for HIV-HCV Coinfection Is Based on the Count of CD4+ lymphocytes Obtained During the Perioperative Period
Therefore, the timing of recommencement of the HAART drug and the preoperative CD4+ lymphocytes counts are both important factors. According to previous reports, prophylaxis against bacterial and viral infections seems to be the same as for liver transplantation without HIV infection. 20 
The Presence of Hemophilia Makes It Diffi cult to Manage the Coagulation Time and Control Bleeding During the Intra-and Postoperative Period Before a Transplanted Liver Starts to Function
Moreover, when considering LDLT and when only carrier-donors exist, an assessment of the risks associated with the resection of the carrier-donor's liver would also be a problem. 37 
Conclusions
This review is an overview of liver transplantation performed to date for HIV-HCV coinfected persons. Although there have been no cadaveric liver transplantations for these patients in Japan, 57 conventional knowledge about cadaveric liver transplantation may be applicable in most cases, despite the unresolved problems. In light of the fact that most of these Japanese patients are the victims of contaminated blood products, we believe that the number of liver transplantations will increase, in the context of medical relief. 58 
